Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company focused on providing specialised services to the pharmaceutical industry, announces that Stuart Jackson, Chief Financial Officer and Board Director has indicated that he will leave the Company in the Summer of 2019 to take up a position as Chief Financial Officer of a listed entity, returning to the energy sector.
Guildford, UK – 13 February 2019: ErgoMed,plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company focused on providing specialised services to the pharmaceutical industry, announces that Stuart Jackson, Chief Financial Officer and Board Director has indicated that he will leave the Company in the Summer of 2019 to take up a position as Chief Financial Officer of a listed entity, returning to the energy sector.
Stuart will continue as a Board Director and Chief Financial Officer of Ergomed PLC until a replacement has been secured in order to ensure a smooth transition process. A search for his replacement is underway and the Company will provide an update on his successor in due course.
Dr Miroslav Reljanovic, Executive Chairman of Ergomed, said: “I would like to thank Stuart for his support and contribution to Ergomed. In the time he has been with us, he has made a positive impact on the business and has strengthened our finance and reporting capabilities. I look forward to continuing to work closely with him over the coming months whilst we select his successor. We wish Stuart every success in his new role.”
- Ends -
Enquiries:
| Ergomed plc | Tel: +44 (0) 1483 402 975 |
| Miroslav Reljanovic (Executive Chairman) |
|
| Stuart Jackson (Chief Financial Officer) |
|
|
| |
| Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
| Michael Meade / Freddie Barnfield (Nominated Adviser) |
|
| James Black (Joint Broker) |
|
|
| |
|
| |
| Consilium Strategic Communications – for UK enquiries | Tel: +44 (0) 20 3709 5700 |
| Chris Gardner / Mary-Jane Elliott | |
| Matthew Neal / Olivia Manser |
|
|
| |
| MC Services – for Continental European enquiries | Tel: +49 211 5292 5222 |
| Anne Hennecke |
|
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
